Erica Garza
Family · Grandview, WANPI 1598851784
Payments from drug & device makers
Across 110 payments — averaging $21.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$628
- AbbVie$598
- Novo Nordisk$209
- Bayer$156
- Sunovion Pharmaceuticals Inc.$147
- Daiichi Sankyo Inc.$125
- plus $508 from 15 others
What the payments were for
- Food & beverage$2,372100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 19 | $628 |
| AbbVie | 26 | $598 |
| Novo Nordisk | 11 | $209 |
| Bayer | 8 | $156 |
| Sunovion Pharmaceuticals Inc. | 13 | $147 |
| Daiichi Sankyo Inc. | 5 | $125 |
| GSK | 5 | $98 |
| Lilly USA, LLC | 3 | $69 |
| Sanofi Pasteur Inc. | 4 | $64 |
| Pfizer | 3 | $48 |
| Merck | 2 | $35 |
| Otsuka America Pharmaceutical, Inc. | 1 | $28 |
| Supernus Pharmaceuticals, Inc. | 2 | $25 |
| Teva Pharmaceuticals USA, Inc. | 1 | $24 |
| Harmony Biosciences LLC | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Ironshore Pharmaceuticals Inc. | 1 | $18 |
| Mylan Specialty L.p. | 1 | $16 |
| Dexcom, Inc. | 1 | $16 |
| Amgen | 1 | $13 |
| Organon | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,372 in reported general payments places this provider in the 90th percentile of 1,706 family providers in Washington.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xigduo XrDapaglifloz Propaned/Metformin | 99 | $93,723 |
| OzempicSemaglutide | 53 | $64,738 |
| FarxigaDapagliflozin Propanediol | 31 | $26,037 |
| TrulicityDulaglutide | 25 | $23,539 |
| JanuviaSitagliptin Phosphate | 15 | $10,377 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $8,485 |
| MyrbetriqMirabegron | 13 | $5,606 |
| DuleraMometasone/Formoterol | 13 | $4,237 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $2,639 |
| Losartan Potassium | 158 | $1,578 |
| Levothyroxine Sodium | 119 | $1,377 |
| Atorvastatin Calcium | 127 | $1,188 |
| Pravastatin Sodium | 61 | $1,136 |
| Omeprazole | 67 | $1,055 |
| Duloxetine Hcl | 38 | $779 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $209 | $64,73853 claims |
| AstraZenecaFarxiga | $628 | $26,03731 claims |
| Lilly USA, LLCTrulicity | $69 | $23,53925 claims |
| MerckJanuvia, Dulera | $35 | $14,61428 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,706 family providers in Washington.
Other family in Grandview
- Patric SchineCentralia$842K
- Sharla PetersonKenmore$192K
- Zelda SwainSpokane$83K
- Savannah MorganRenton$76K
- Kevan PettersonSeattle$56K
- Kelly McFeeSunnyside$42K
- Cheryl SomersSpokane$31K
- Hye-Jin GehringBellevue$30K
- Kaitlin BrasierSeattle$29K
- Karen JohnsonSeattle$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.